Detalhe da pesquisa
1.
Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
N Engl J Med
; 373(15): 1418-28, 2015 Oct 08.
Artigo
Inglês
| MEDLINE | ID: mdl-26444729
2.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.
Lancet
; 381(9884): 2167-75, 2013 Jun 22.
Artigo
Inglês
| MEDLINE | ID: mdl-23562009
3.
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b study.
Mult Scler
; 18(3): 314-21, 2012 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-21878455
4.
Toward more efficient clinical trials for amyotrophic lateral sclerosis.
Amyotroph Lateral Scler
; 11(3): 259-65, 2010 May 03.
Artigo
Inglês
| MEDLINE | ID: mdl-19961263
5.
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Lancet
; 372(9648): 1463-72, 2008 Oct 25.
Artigo
Inglês
| MEDLINE | ID: mdl-18970976
6.
The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction.
Patient Prefer Adherence
; 11: 33-45, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28053511
7.
First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica.
PLoS One
; 10(5): e0125034, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25962165
8.
Case records of the Massachusetts General Hospital. Case 22-2006--a 77-year-old man with a rapidly progressive gait disorder.
N Engl J Med
; 355(3): 296-304, 2006 Jul 20.
Artigo
Inglês
| MEDLINE | ID: mdl-16855271
9.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
Lancet Neurol
; 13(5): 472-81, 2014 May.
Artigo
Inglês
| MEDLINE | ID: mdl-24656609
10.
Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials.
PLoS One
; 7(10): e45409, 2012.
Artigo
Inglês
| MEDLINE | ID: mdl-23049678
11.
[Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis]. / Sensibilidad de la escala ampliada del estado de discapacidad (EDSS) a la progresión de la enfermedad y la intervención terapéutica en las formas progresivas de la esclerosis múltiple.
Rev Neurol
; 51(6): 321-9, 2010 Sep 16.
Artigo
Espanhol
| MEDLINE | ID: mdl-20839168
12.
An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers.
Clin Neuropharmacol
; 33(2): 55-60, 2010.
Artigo
Inglês
| MEDLINE | ID: mdl-20375654
13.
Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Lancet Neurol
; 9(4): 381-90, 2010 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-20163990
14.
Seven-Tesla proton magnetic resonance spectroscopic imaging in adult X-linked adrenoleukodystrophy.
Arch Neurol
; 65(11): 1488-94, 2008 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-19001168
15.
Sixteen novel mutations in the Cu/Zn superoxide dismutase gene in amyotrophic lateral sclerosis: a decade of discoveries, defects and disputes.
Amyotroph Lateral Scler Other Motor Neuron Disord
; 4(2): 62-73, 2003 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-14506936
16.
Inherited disorders of the neuromuscular junction.
Int Anesthesiol Clin
; 44(2): 91-106, 2006.
Artigo
Inglês
| MEDLINE | ID: mdl-16849958
17.
Acquired disorders of the neuromuscular junction.
Int Anesthesiol Clin
; 44(2): 107-21, 2006.
Artigo
Inglês
| MEDLINE | ID: mdl-16849959